Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

Axel Grothey

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial'. Together they form a unique fingerprint.